Skip to main content
. 2018 Nov 13;39(1):121–130. doi: 10.1007/s00296-018-4195-x

Fig. 1.

Fig. 1

Severity of PsA prior to and when receiving treatment based on patient self-report in US and EU5 patients. *p < 0.05; **p < 0.01 for patients with moderate-to-severe disease receiving advance therapies vs. other therapies within the respective region. EU5 France, Germany, Italy, Spain, UK; PsA psoriatic arthritis